2023
AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review
Garcia-Tsao G, Abraldes J, Rich N, Wong V. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review. Gastroenterology 2023, 166: 202-210. PMID: 37978969, DOI: 10.1053/j.gastro.2023.10.016.Peer-Reviewed Original ResearchConceptsSpontaneous bacterial peritonitisAcute kidney injuryLarge-volume paracentesisEffective arterial blood volumeVasoactive drugsVariceal hemorrhageArterial blood volumeHRS-AKIUncomplicated ascitesIntravenous albuminVolume statusPractice UpdateBlood volumeChronic liver failure grade 3Best practice advice statementsClinical Practice Updates CommitteeEnd-stage liver diseaseAGA Clinical Practice UpdateForms of AKIIntensive care unit monitoringAGA Governing BoardCombination of vasoconstrictorsInitial endoscopic hemostasisPatient's volume statusClinical Practice Update
2011
Ascites
Garcia‐Tsao G. Ascites. 2011, 210-233. DOI: 10.1002/9781444341294.ch10.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHepatorenal syndromeBacterial infectionsBaseline renal dysfunctionPeripheral arterial vasodilatationAcute kidney injurySecond-line treatmentMainstay of treatmentSpontaneous bacterial peritonitisSympathetic nervous systemEffective blood volumeSpontaneous bacterial infectionsCommon bacterial infectionsSigns of infectionLong-term safetyDiagnostic paracentesisIntravenous albuminPrerenal typeSinusoidal hypertensionAldosterone systemArterial vasodilatationKidney injuryLiver transplantationRefractory ascitesRenal dysfunctionSodium restrictionVasoconstrictor Therapy for Hepatorenal Syndrome
Yeo C, Garcia-Tsao G. Vasoconstrictor Therapy for Hepatorenal Syndrome. Frontiers Of Gastrointestinal Research 2011, 28: 149-162. DOI: 10.1159/000318997.Peer-Reviewed Original ResearchHepatorenal syndromeReceptor agonistClinical trialsEffective arterial blood volumeType 2 hepatorenal syndromeAlpha-adrenergic receptor agonistIschemic adverse eventsNeurohormonal system activationPreferred alternative therapyRenal function effectsFirst-line therapyMain pathogenic mechanismRandomized clinical trialsAdrenergic receptor agonistArterial blood volumeVasopressin receptor agonistSuboptimal study designEase of administrationOral midodrineRenal vasoconstrictionSystemic vasodilatationVasoconstrictor therapyDefinitive therapyIntravenous albuminKidney injury
2002
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis
Ginès P, Uriz J, Calahorra B, Garcia–Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodés J, Cirrhosis F. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002, 123: 1839-1847. PMID: 12454841, DOI: 10.1053/gast.2002.37073.Peer-Reviewed Original ResearchMeSH KeywordsAscitesBacterial InfectionsFemaleGastrointestinal HemorrhageHepatic EncephalopathyHormonesHumansInjections, IntravenousKidneyLiverLiver CirrhosisMaleMiddle AgedParacentesisPeritonitisPortasystemic Shunt, Transjugular IntrahepaticRetreatmentSerum AlbuminSeverity of Illness IndexSurvival AnalysisConceptsTransjugular intrahepatic portosystemic shuntRefractory ascitesParacentesis groupLiver transplantationHepatorenal syndromeTIPS groupTransjugular intrahepatic portosystemic shuntingBlood urea nitrogen levelsChild-Pugh scoreComplications of cirrhosisIntrahepatic portosystemic shuntRecurrence of ascitesSevere hepatic encephalopathyUrea nitrogen levelsIntravenous albuminPrimary endpointSecondary endpointsHepatic encephalopathyPortosystemic shuntingPortosystemic shuntAscites recurrenceParacentesisHealthcare costsAscitesProbability of survival
1991
Treatment of ascites with A single total paracentesis
Garcia-Tsao G. Treatment of ascites with A single total paracentesis. Hepatology 1991, 13: 1005-1007. PMID: 2029984, DOI: 10.1002/hep.1840130534.Peer-Reviewed Original ResearchConceptsPlasma renin activityEffective intravascular volumeTotal paracentesisCauses of readmissionLarge-volume paracentesisTense ascitesCirrhotic patientsProbability of readmissionRenin activityDextran 70Intravenous albuminRenal impairmentAldosterone concentrationClinical courseIntravascular volumeAscitic fluidTherapeutic proceduresEffects of paracentesisFirst hospital stayStandard liver testsRenal function testsGroup of patientsTreatment of ascitesFree water clearanceCause of death